Amicus Therapeutics - FOLD Stock Forecast, Price & News

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group assumed coverage on Amicus Therapeutics in a research report on Wednesday, April 13th. They issued a "neutral" rating for the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Amicus Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $15.25.

Amicus Therapeutics Price Performance

NASDAQ:FOLD traded down $0.27 during mid-day trading on Tuesday, hitting $12.27. The company's stock had a trading volume of 172,350 shares, compared to its average volume of 3,080,933. The company has a market capitalization of $3.44 billion, a price-to-earnings ratio of -12.67 and a beta of 0.96. The company has a current ratio of 3.02, a quick ratio of 2.90 and a debt-to-equity ratio of 2.25. Amicus Therapeutics has a fifty-two week low of $5.91 and a fifty-two week high of $12.73. The stock has a fifty day moving average of $10.05 and a 200-day moving average of $9.04.

Amicus Therapeutics (NASDAQ:FOLD - Get Rating) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02. Amicus Therapeutics had a negative return on equity of 102.55% and a negative net margin of 87.50%. During the same period in the previous year, the firm posted ($0.19) earnings per share. As a group, equities analysts forecast that Amicus Therapeutics will post -0.88 EPS for the current fiscal year.

Insider Buying and Selling at Amicus Therapeutics

In related news, CEO John F. Crowley sold 11,346 shares of the stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $8.00, for a total transaction of $90,768.00. Following the completion of the sale, the chief executive officer now owns 932,807 shares in the company, valued at approximately $7,462,456. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Amicus Therapeutics news, CEO John F. Crowley sold 10,468 shares of Amicus Therapeutics stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $8.01, for a total value of $83,848.68. Following the completion of the transaction, the chief executive officer now owns 922,339 shares in the company, valued at approximately $7,387,935.39. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO John F. Crowley sold 11,346 shares of the firm's stock in a transaction on Friday, June 3rd. The shares were sold at an average price of $8.00, for a total value of $90,768.00. Following the completion of the sale, the chief executive officer now owns 932,807 shares of the company's stock, valued at $7,462,456. The disclosure for this sale can be found here. Over the last three months, insiders sold 130,779 shares of company stock valued at $1,237,966. 2.10% of the stock is currently owned by company insiders.